托法替布逆转自噬缺陷诱导的IL-6过表达:对干燥综合征的意义
研究分析12例低灶性评分pSS患者与10例对照的唇腺活检,发现pSS患者唇腺上皮细胞p62升高、ATG5降低,且与JAK-STAT通路活化负相关;ATG5缺陷3D腺泡重现IL-6等炎症标志物升高,托法替布可逆转该效应。
要点
- pSS患者唇腺上皮细胞自噬缺陷,p62升高、ATG5降低。
- 自噬缺陷与JAK-STAT通路活化及IL-6过表达相关。
- 托法替布可逆转ATG5缺陷3D腺泡的炎症标志物升高。
核心结论
- pSS患者唇腺上皮细胞ATG5表达降低可能通过JAK-STAT通路活化促进炎症。
- 托法替布或可作为pSS患者的抗炎药物。
研究设计与样本
- 分析12例低灶性评分pSS患者与10例对照的唇腺活检。
- 构建ATG5缺陷3D腺泡,在有无托法替布条件下与IL-6共孵育。
- 采用PCR或western blot评估自噬标志物、促炎因子表达及JAK-STAT通路活化。
主要发现
- pSS患者唇腺p62升高、ATG5降低,与pSTAT1和pSTAT3活化增加负相关。
- STAT1和IL-6表达升高与EULAR Sjögren's syndrome disease activity index及抗Ro抗体存在相关。
- ATG5缺陷3D腺泡重现pSS唇腺发现,IL-6等促炎标志物表达升高,托法替布可逆转。
临床怎么用
- pSS患者唇腺上皮细胞自噬缺陷与JAK-STAT通路活化相关,提示托法替布可能用于抗炎治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Altered homeostasis of salivary gland (SG) epithelial cells in Sjögren's syndrome (SS) could be the initiating factor that leads to inflammation, secretory dysfunction and autoimmunity. Autophagy is an important homeostatic mechanism, whose deficiency is associated with inflammation and accumulation of Janus kinase (JAK)-signal transducer and activator of transcription (STAT) components. We aimed to evaluate whether autophagy is altered in labial SG (LSG) epithelial cells from primary SS (pSS) patients and whether this contributes to inflammation through the JAK-STAT pathway. Furthermore, we investigated the anti-inflammatory effect of the JAK inhibitor tofacitinib in autophagy-deficient (ATG5 knockdown) three-dimensional (3D)-acini. METHODS: We analysed LSG biopsies from 12 pSS patients with low focus score and 10 controls. ATG5-deficient 3D-acini were generated and incubated with IL-6 in the presence or absence of tofacitinib. Autophagy markers, pro-inflammatory cytokine expression, and JAK-STAT pathway activation were evaluated by PCR or western blot, along with correlation analyses between the evaluated markers and clinical parameters. RESULTS: LSG from pSS patients showed increased p62 and decreased ATG5 expression, correlating negatively with increased activation of JAK-STAT pathway components (pSTAT1 and pSTAT3). Increased expression of STAT1 and IL-6 correlated with EULAR Sjögren's syndrome disease activity index and the presence of anti-Ro antibodies. ATG5-deficient 3D-acini reproduced the findings observed in LSG from pSS patients, showing increased expression of pro-inflammatory markers such as IL-6, which was reversed by tofacitinib. CONCLUSION: Decreased expression of ATG5 in LSG epithelial cells from pSS patients possibly contributes to increased inflammation associated with JAK-STAT pathway activation, as evidenced in ATG5-deficient 3D-acini. Interestingly, these results suggest that tofacitinib could be used as an anti-inflammatory agent in pSS patients.
引用
- Barrera MJ, Aguilera S, Castro I, et al. Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sjögren's syndrome. Rheumatology (Oxford). 2021. PMID: 33216905. doi:10.1093/rheumatology/keaa670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。